Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...

There were no studies that specifically studied the effect of enteral lipids in infants at risk of liver disease or who have liver disease due to prolonged need for artificial nutrition secondary to ...

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in ...

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in ...

Patients with severe intestinal failure will receive quicker treatment, following the opening of a new specialist unit at a hospital. The unit, at University Hospital, Coventry, is staffed by ...

Jaguar Health, Inc. family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first short bowel syndrome with intestinal failure (SBS-IF) patient has been dosed in the ...

2006年8月と2006年12月の2回、以下の検索語を単独または組み合わせてMEDLINE検索を行った。「腸管移植（intestinal transplant）」「小腸移植（small bowel transplant）」「短腸症候群（short bowel syndrome）」「腸管不全（intestinal failure）」。全文が発表されている原著論文を ...

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the November 8, 2025 ...

VectivBio Holding AG (VectivBio), a clinical-stage biopharmaceutical company, announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s phase 3 STARS (STudy of ...